NABTT 0502

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项试验的主要目标是评估这种联合方案治疗11例复发性多形性胶质母细胞瘤成人患者的总体存活率。次要目标是评估和评估毒性、肿瘤应答率和6个月无进展生存期，并描述这种给药途径的药代动力学。在美国，每年诊断出35,000例原发脑瘤。由于超过50%的原发脑肿瘤是恶性胶质瘤，预计每年将发生超过18,000例胶质母细胞瘤和间变性星形细胞瘤。尽管与乳腺癌或肺癌等其他癌症相比，脑瘤并不常见，但由于它们会导致严重的神经功能障碍，它们给患者、配偶和家人造成了巨大的损失。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this trial is to estimate the overall survival rate associated with this combined regimen in treating adult patients wit11 recurrent glioblastoma multiforme. The secondary objectives are to assess and estimate toxicities, tumor response rate, 6 month progression free survival & to describe the pharrnacokinetics of this route of administration. In the United States 35,000 primary brain tumors are diagnosed each year. Since more than 50% of primary brain tumors are malignant gliomas, upwards of 18,000 new cases of glioblastorna and anaplastic astrocytoma can be expected to occur yearly. Although brain tumors are uncommon in comparison with other cancers such as breast or lung cancer, they exact a tremendous toll upon patients, spouses and families because of the severe neurologic disability they produce.